Reaz Uddin

Dr. Reaz Uddin


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Biologicals
Verified
Journal Article
Closed access
NENosheen Ehsan
Nosheen Ehsan
Sajjad AhmadSajjad Ahmad
Sajjad Ahmad
SASyed Sikander Azam
Syed Sikander Azam
TRThanyada Rungrotmongkol
Thanyada Rungrotmongkol
RUReaz Uddin
Reaz Uddin

18 May 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
KKKanwal Khan
Kanwal Khan
ZBZarrin Basharat
Zarrin Basharat
KJKhurshid Jalal
Khurshid Jalal
MMMutaib Mashraqi
Mutaib Mashraqi
AAAhmad Alzamami
Ahmad Alzamami
RUReaz Uddin
Reaz Uddin
Campylobacter ureolyticus is a Gram-negative, anaerobic, non-spore-forming bacteria that causes gastrointestinal infections. Being the most prevalent cause of bacterial enteritis globally, infection by this bacterium is linked with significant morbidity and mortality in children and immunocompromised patients. No information on pan-therapeutic drug targets for this species is available yet. In the current study, a pan-genome analysis was performed on 13 strains of C. ureolyticus to prioritize potent drug targets from the identified core genome. In total, 26 druggable proteins were identified using subtractive genomics. To the best of the authors’ knowledge, this is the first report on the mining of drug targets in C. ureolyticus. UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) was selected as a promiscuous pharmacological target for virtual screening of two bacterial-derived natural product libraries, i.e., postbiotics (n = 78) and streptomycin (n = 737) compounds. LpxC inhibitors from the ZINC database (n = 142 compounds) were also studied with reference to LpxC of C. ureolyticus. The top three docked compounds from each library (including ZINC26844580, ZINC13474902, ZINC13474878, Notoginsenoside St-4, Asiaticoside F, Paraherquamide E, Phytoene, Lycopene, and Sparsomycin) were selected based on their binding energies and validated using molecular dynamics simulations. To help identify potential risks associated with the selected compounds, ADMET profiling was also performed and most of the compounds were considered safe. Our findings may serve as baseline information for laboratory studies leading to the discovery of drugs for use against C. ureolyticus infections.